The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.